Next Article in Journal
Fungicidal Activity in the Presence of Keratin as an Important Factor Contributing to In Vivo Efficacy: A Comparison of Efinaconazole, Tavaborole, and Ciclopirox
Next Article in Special Issue
Morphology Changes in Human Fungal Pathogens upon Interaction with the Host
Previous Article in Journal
The Human Mucosal Mycobiome and Fungal Community Interactions

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

by 1,2,3,†, 2,3,4,†, 2,3 and 1,2,3,4,*
The National Aspergillosis Center, Education and Research Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK
Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK
Global Action Fund for Fungal Infections, 1211 Geneva 1, Switzerland
Manchester Fungal Infection Group, Core Technology Facility, The University of Manchester, Manchester M13, 9PL, UK
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Fungi 2017, 3(4), 57;
Received: 22 September 2017 / Revised: 12 October 2017 / Accepted: 16 October 2017 / Published: 18 October 2017
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative. View Full-Text
Keywords: global prevalence; fungal diseases; estimate precision global prevalence; fungal diseases; estimate precision
Show Figures

Graphical abstract

MDPI and ACS Style

Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi 2017, 3, 57.

AMA Style

Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. Journal of Fungi. 2017; 3(4):57.

Chicago/Turabian Style

Bongomin, Felix, Sara Gago, Rita O. Oladele, and David W. Denning. 2017. "Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision" Journal of Fungi 3, no. 4: 57.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop